top of page
​BioFinland Member

BioFinland Member

TILT Biotherapeutics

TILT Biotherapeutics
Company name

TILT Biotherapeutics


Haartmaninkatu 3C, FI-00290 Helsinki






Contact person

Aino Kalervo


Akseli Hemminki

Main categories

Drug Discovery and Development / Drug Delivery, Pharmaceutical

Last updated

5 March 2018

Company profile

TILT Biotherapeutics is developing a breakthrough treatment for cancer with oncolytic immunotherapy. Advanced solid tumors are currently incurable and limited treatment options are available – preclinical data on TILT technology suggests curative potential. The company was founded in 2013 and its lead product (TILT-123) is now in late preclinical stage with Phase I clinical trials starting soon. TILT’s patented technology involves utilization of oncolytic viruses for enhancement of T-cell therapy. Initial embodiments of the technology are used to enable tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T), and checkpoint inhibiting antibody (anti-PD1) therapy of solid tumors.

bottom of page